Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4991-5000

  Cigana, Cristina ^a   Bernardini, Francesca ^b   Facchini, Marcella ^a   Alcalá Franco, Beatriz ^a   Riva, Camilla ^a   De Fino, Ida ^a   Rossi, Alice ^a   Ranucci, Serena ^a   Misson, Pauline ^b   Chevalier, Eric ^b   Brodmann, Maj ^b   Schmitt, Michel ^b   Wach, Achim ^b   Dale, Glenn E ^b   Obrecht, Daniel ^b   Bragonzi, Alessandra ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Polyphor Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; EPITOPE; POL7001; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM ISOLATE; BODY WEIGHT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; IN VITRO STUDY; LUNG BURDEN; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; C57BL MOUSE; DRUG EFFECTS; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; LUNG; MALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84979268200     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00390-16     Document Type: Article

References (39)

1. Moss RB. 2010. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 16:598-603. http://dx.doi.org/10.1097/MCP.0b013e32833e24a6.
2. Cystic Fibrosis Foundation. 2013. Patient registry. Annual data report 2012. http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/.
3. Gellatly SL, Hancock RE. 2013. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67:159-173. http://dx.doi.org/10.1111/2049-632X.12033.
4. Projan SJ, Youngman PJ. 2002. Antimicrobials: new solutions badly needed. Curr Opin Microbiol 5:463-465. http://dx.doi.org/10.1016/S1369-5274(02)00364-8.
5. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Kach A, Eberl L, Riedel K, DeMarco SJ, Robinson JA. 2010. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010-1013. http://dx.doi.org/10.1126/science.1182749.
6. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964. http://dx.doi.org/10.1038/35023079.
7. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, Morales G, Kohler T, van Delden C, Weinel C, Slickers P, Tummler B. 2007. Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 104:8101-8106. http://dx.doi.org/10.1073/pnas.0609213104.
8. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. 2004. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59:334-336. http://dx.doi.org/10.1136/thx.2003.014258.
9. Bezuidt OK, Klockgether J, Elsen S, Attree I, Davenport CF, Tummler B. 2013. Intraclonal genome diversity of Pseudomonas aeruginosa clones CHA and TB. BMC Genomics 14:416. http://dx.doi.org/10.1186/1471-2164-14-416.
10. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Doring G, Tummler B. 2009. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180:138-145. http://dx.doi.org/10.1164/rccm.200812-1943OC.
11. Bragonzi A, Wiehlmann L, Klockgether J, Cramer N, Worlitzsch D, Doring G, Tummler B. 2006. Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 152:3261-3269. http://dx.doi.org/10.1099/mic.0.29175-0.
12. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. 1994. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266:1705-1708. http://dx.doi.org/10.1126/science.7527588.
13. Facchini M, De Fino I, Riva C, Bragonzi A. 17 March 2014. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp http://dx.doi.org/10.3791/51019.
14. Lorè NI, Cigana C, De Fino I, Riva C, Juhas M, Schwager S, Eberl L, Bragonzi A. 2012. Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One 7:e35648. http://dx.doi.org/10.1371/journal.pone.0035648.
15. van Heeckeren AM, Schluchter MD. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:291-312. http://dx.doi.org/10.1258/002367702320162405.
16. van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, Erokwu B, Haxhiu MA, Ferkol TW. 2000. Effect of Pseudomonas aeruginosa infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med 161:271-279. http://dx.doi.org/10.1164/ajrccm.161.1.9903019.
17. Kukavica-Ibrulj I, Facchini M, Cigana C, Levesque RC, Bragonzi A. 2014. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection. Methods Mol Biol 1149:757-771. http://dx.doi.org/10.1007/978-1-4939-0473-0-58.
18. CLSI. 2014. CLSI M100-S24. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. Clinical and Laboratory Standards Institute, Wayne, Pa.
19. Cramer N, Wiehlmann L, Ciofu O, Tamm S, Hoiby N, Tummler B. 2012. Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis. PLoS One 7:e50731. http://dx.doi.org/10.1371/journal.pone.0050731.
20. Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tummler B, Cariani L, Conese M, Doring G, Bragonzi A. 2007. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153:1445-1454. http://dx.doi.org/10.1099/mic.0.2006/003400-0.
21. Alcalá-Franco B, Montanari S, Cigana C, Bertoni G, Oliver A, Bragonzi A. 2012. Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. J Antimicrob Chemother 67:962-969. http://dx.doi.org/10.1093/jac/dkr587.
22. Römling U, Kader A, Sriramulu DD, Simm R, Kronvall G. 2005. Worldwide distribution of Pseudomonas aeruginosa clone C strains in the aquatic environment and cystic fibrosis patients. Environ Microbiol 7:1029-1038. http://dx.doi.org/10.1111/j.1462-2920.2005.00780.x.
23. Justo JA, Danziger LH, Gotfried MH. 2013. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis 7:272-287. http://dx.doi.org/10.1177/1753465813487412.
24. Bragonzi A, Worlitzsch D, Pier GB, Timpert P, Ulrich M, Hentzer M, Andersen JB, Givskov M, Conese M, Doring G. 2005. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis 192:410-419. http://dx.doi.org/10.1086/431516.
25. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254. http://dx.doi.org/10.1126/science.288.5469.1251.
26. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML. 2005. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293:581-588. http://dx.doi.org/10.1001/jama.293.5.581.
27. Ferroni A, Guillemot D, Moumile K, Bernede C, Le Bourgeois M, Waernessyckle S, Descamps P, Sermet-Gaudelus I, Lenoir G, Berche P, Taddei F. 2009. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr Pulmonol 44:820-825. http://dx.doi.org/10.1002/ppul.21076.
28. Bragonzi A. 2010. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300:584-593. http://dx.doi.org/10.1016/j.ijmm.2010.08.012.
29. Moalli F, Paroni M, Veliz Rodriguez T, Riva F, Polentarutti N, Bottazzi B, Valentino S, Mantero S, Nebuloni M, Mantovani A, Bragonzi A, Garlanda C. 2011. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol 186:5425-5434. http://dx.doi.org/10.4049/jimmunol.1002035.
30. Yu H, Boucher JC, Hibler NS, Deretic V. 1996. Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE). Infect Immun 64:2774-2781.
31. Zarogoulidis P, Kioumis I, Porpodis K, Spyratos D, Tsakiridis K, Huang H, Li Q, Turner JF, Browning R, Hohenforst-Schmidt W, Zarogoulidis K. 2013. Clinical experimentation with aerosol antibiotics: current and future methods of administration. Drug Des Devel Ther 7:1115-1134. http://dx.doi.org/10.2147/DDDT.S51303.
32. Ratjen F, Munck A, Kho P, Angyalosi G. 2010. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65:286-291. http://dx.doi.org/10.1136/thx.2009.121657.
33. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317-325. http://dx.doi.org/10.1172/JCI0213870.
34. Cigana C, Lore NI, Riva C, De Fino I, Spagnuolo L, Sipione B, Rossi G, Nonis A, Cabrini G, Bragonzi A. 2016. Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Sci Rep 6:21465. http://dx.doi.org/10.1038/srep21465.
35. Döring G, Bragonzi A, Paroni M, Akturk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhaufl M, Wagner TO, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M. 2014. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13:156-163. http://dx.doi.org/10.1016/j.jcf.2013.10.007.
36. Stangl R. 2008. A nebulizer for rodent inhalation studies. Respir Drug Deliv 3:697-700. http://www.rddonline.com/publications/articles/article.php?ArticleID=1218&return=1.
37. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. 2005. Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61:214-218. http://dx.doi.org/10.1016/j.ejpb.2005.04.009.
38. Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. 2009. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:3923-3928. http://dx.doi.org/10.1128/AAC.00268-09.
39. Sherrard LJ, Tunney MM, Elborn JS. 2014. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 384:703-713. http://dx.doi.org/10.1016/S0140-6736(14)61137-5.